Frank Himmelsbach

4.2k citations

30 papers · 3.4k indexed · 3 hit papers · h-index 16

Oncology top 2%
Molecular Biology top 5%
Pulmonary and Respiratory Medicine top 2%
Endocrinology, Diabetes and Metabolism top 1%
Organic Chemistry top 5%

Co-authors: Flavio Solca Matthias Eckhardt Leo Thomas Anke Baum Wolfgang J. Rettig Geoffrey I. Shapiro Lucian R. Chirieac Kah Keng Wong
Topics: DNA and Nucleic Acid Chemistry (7 papers)Diabetes Treatment and Management (5 papers)Biochemical and Molecular Research (4 papers)
Cited by: Oncology Endocrinology, Diabetes and Metabolism Pulmonary and Respiratory Medicine
Journals: Circulation Oncogene Journal of Medicinal Chemistry
Partner nations: Germany Austria United States

In The Last Decade

Frank Himmelsbach

29 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

2008 1.2k citations Lauren Ambrogio, Takeshi Shimamura et al. Oncogene profile →
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

2012 684 citations Flavio Solca, Andreas Zoephel et al. Journal of Pharmacology and Experimental Therapeutics profile →
Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

2011 494 citations Rolf Grempler, Leo Thomas et al. Diabetes Obesity and Metabolism profile →

Peers

Countries citing papers authored by Frank Himmelsbach

Since Specialization

Citations

This map shows the geographic impact of Frank Himmelsbach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Himmelsbach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Himmelsbach more than expected).

Fields of papers citing papers by Frank Himmelsbach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Himmelsbach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Himmelsbach. The network helps show where Frank Himmelsbach may publish in the future.

Co-authorship network of co-authors of Frank Himmelsbach

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Himmelsbach. A scholar is included among the top collaborators of Frank Himmelsbach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Himmelsbach. Frank Himmelsbach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Photocatalytic synthesis of homoallylic amines via nucleophilic addition of nickel allyl complexes to imines 2025 ·Chemical Science ·(unknown),Nikolaus Müller,(unknown),Frank Himmelsbach,(unknown),Bernhard Breit	0
2	SGLT6 - A pharmacological target for the treatment of obesity? 2018 ·Adipocyte ·(unknown),Matthias Eckhardt,Frank Himmelsbach,Achim Sauer,Birgit Stierstorfer,Bradford S. Hamilton	15
3	Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes 2014 ·European Journal of Pharmacology ·Bradford S. Hamilton,Frank Himmelsbach,Herbert Nar,(unknown),Paula M. Krosky,(unknown),Rong Guo,Shi Meng,Yi Zhao,Deepak S. Lala,Linghang Zhuang,David A. Claremon,Gerard M. McGeehan	25
4	Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blockerbreakdown → 2012 ·Journal of Pharmacology and Experimental Therapeutics ·Flavio Solca,(unknown),Andreas Zoephel,Gerd Bader,Michael P. Sanderson,Christian Klein,Oliver Kraemer,Frank Himmelsbach,Eric Haaksma,Guenther R. Adolf	684
5	Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats 2011 ·Diabetes Obesity and Metabolism ·Leo Thomas,Rolf Grempler,Matthias Eckhardt,Frank Himmelsbach,Achim Sauer,Thomas Klein,Peter Eickelmann,Michael Mark	42
6	Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitorsbreakdown → 2011 ·Diabetes Obesity and Metabolism ·Rolf Grempler,Leo Thomas,Matthias Eckhardt,Frank Himmelsbach,Achim Sauer,Dale E. Sharp,Remko A. Bakker,Michael Mark,Thomas Klein,Peter Eickelmann	494
7	(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors 2008 ·Journal of Pharmacology and Experimental Therapeutics ·Leo Thomas,Matthias Eckhardt,Elke Langkopf,Moh Tadayyon,Frank Himmelsbach,Mark Michael	244
8	3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: A class of potent DPP-4 inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Matthias Eckhardt,Norbert Hauel,Frank Himmelsbach,Elke Langkopf,Herbert Nar,Michael Mark,Moh Tadayyon,Leo Thomas,Brian D. Guth,Ralf Lotz	28
9	Synthesis of 2-bromo-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one and 3-alkyl-2-bromo-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one and their selective elaboration 2008 ·Tetrahedron Letters ·Matthias Eckhardt,Norbert Hauel,Elke Langkopf,Frank Himmelsbach	3
10	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsbreakdown → 2008 ·Oncogene ·(unknown),Lauren Ambrogio,Takeshi Shimamura,Shigeto Kubo,Masaya Takahashi,Lucian R. Chirieac,Robert F. Padera,Geoffrey I. Shapiro,Anke Baum,Frank Himmelsbach,Wolfgang J. Rettig,Matthew Meyerson,Flavio Solca,Heidi Greulich,Kah Keng Wong	1160
11	567 POSTER Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agents 2006 ·European Journal of Cancer Supplements ·Flavio Solca,Anke Baum,Frank Himmelsbach,A. Amelsberg,(unknown)	15
12	Inhibition of Epidermal Growth Factor Receptor Activity by Two Pyrimidopyrimidine Derivatives 2004 ·Journal of Pharmacology and Experimental Therapeutics ·Flavio Solca,Anke Baum,Elke Langkopf,(unknown),Karl‐Heinz Heider,Frank Himmelsbach,J. C. A. van Meel	39
13	A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity. 1999 ·PubMed ·Christian Stratowa,Anke Baum,M Castañón,(unknown),Frank Himmelsbach,Adolf Himmler,(unknown),Thomas Metz,R. Schnitzer,Flavio Solca,Walter Spevak,Ulrike Tontsch,(unknown)	7
14	Nucleotides, Part LXIII, New 2-(4-Nitrophenyl)ethyl(Npe)- and 2-(4-Nitrophenyl)ethoxycarbonyl(Npeoc)-Protected 2′-Deoxyribonucleosides and Their 3′-Phosphoramidites - Versatile Building Blocks for Oligonucleotide Synthesis 1999 ·Helvetica Chimica Acta ·(unknown),(unknown),Michael Schwarz,(unknown),Bernd Schulz,Frank Himmelsbach,Ramamurthy Charubala,Wolfgang Pfleiderer	10
15	Antagonism of the GPIIb/IIIa Receptor with the Nonpeptidic Molecule BIBU52: Inhibition of Platelet Aggregation In Vitro and Antithrombotic Efficacy In Vivo 1997 ·Journal of Cardiovascular Pharmacology ·Brian D. Guth,Elke Seewaldt-Becker,Frank Himmelsbach,H Weisenberger,Thomas Müller	12
16	Profound and Sustained Inhibition of Platelet Aggregation by Fradafiban, a Nonpeptide Platelet Glycoprotein IIb/IIIa Antagonist, and Its Orally Active Prodrug, Lefradafiban, in Men 1997 ·Circulation ·Thomas Müller,H Weisenberger,(unknown),H. Narjes,Frank Himmelsbach,J. Krause	67
17	DESIGN OF HIGHLY POTENT NONPEPTIDIC FIBRINOGEN RECEPTOR ANTAGONISTS 1995 ·European Journal of Medicinal Chemistry ·Frank Himmelsbach,Volkhard Austel,Brian D. Guth,(unknown),Thomas Müller,(unknown),Elke Seewaldt-Becker,H Weisenberger	11
18	Synthesis of new modified 2′,5′-adenylate trimers carrying 3′-amino-3′-deoxyadenosine at the 2′-terminus 1994 ·Bioorganic & Medicinal Chemistry Letters ·Wolfgang Pfleiderer,Frank Himmelsbach,Ramamurthy Charubala	4
19	Nucleosides. Part LI The 2‐(4‐nitrophenyl)ethoxycarbonyl (npeoc) and 2‐(2,4‐dinitrophenyl)ethoxycarbonyl (dnpeoc) groups for protection of hydroxy functions in ribonucleosides and 2′ ‐deoxyribonucleosides 1993 ·Helvetica Chimica Acta ·(unknown),Frank Himmelsbach,Wolfgang Pfleiderer	27
20	The p-Nitrophenylethyl Group - An Universal Blocking Group in Nucleoside and Nucleotide Chemistry 1985 ·Nucleosides and Nucleotides ·Wolfgang Pfleiderer,Frank Himmelsbach,Ramamurthy Charubala,(unknown),A. Beiter,Bernd Schulz,(unknown)	21

About Frank Himmelsbach

Frank Himmelsbach is a scholar working on Organic Chemistry, Endocrinology, Diabetes and Metabolism and Oncology, having authored 30 papers that have together received 3.4k indexed citations. Recurring topics across this work include DNA and Nucleic Acid Chemistry (7 papers), Diabetes Treatment and Management (5 papers) and Biochemical and Molecular Research (4 papers). The work is most often cited by research in Oncology (1.6k citations), Endocrinology, Diabetes and Metabolism (883 citations) and Pulmonary and Respiratory Medicine (1.3k citations). Frank Himmelsbach has collaborated with scholars based in Germany, Austria and United States. Frequent co-authors include Flavio Solca, Matthias Eckhardt, Leo Thomas, Anke Baum, Wolfgang J. Rettig, Geoffrey I. Shapiro, Lucian R. Chirieac, Kah Keng Wong, Matthew Meyerson and Robert F. Padera. Their work appears in journals such as Circulation, Oncogene and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact